Complementary data for long-term infliximab use in psoriasis - 14/08/14
Funding sources: None. |
|
Disclosure: Dr Menter has sat on the advisory boards of Abbott, Amgen, Galderma, Janssen, and Wyeth; has been a consultant for Abbott, Amgen, Eli Lilly, Galderma, Janssen, LEO Pharma, Stiefel, and Wyeth; has been an investigator for Abbott, Allergan, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Novo Nordisk, Pfizer, Stiefel, Syntrix Biosystems, and Wyeth; has been a speaker for Abbott, Amgen, Galderma, Janssen, LEO Pharma, and Wyeth; and received grants and/or honoraria from Abbott, Allergan, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Novo Nordisk, Pfizer, Stiefel, Syntrix Biosystems, and Wyeth. Dr Mansouri has no conflicts of interest to declare. |
Vol 71 - N° 3
P. 591 - septembre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?